

Haematologica
HAEMATOL/2016/144949
Version 4

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Fausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, Bruno Martino, Mariella D'Adda, Fabio Stagno, Angelo Michele Carella, Paolo Avanzini, Mario Tiribelli, Elena Trabacchi, Giuseppe Visani, Marco Gobbi, Marzia Salvucci, Luciano Levato, Gianni Binotto, Silvana Franca Capalbo, Maria Teresa Bochicchio, Simona Soverini, Michele Cavo, Giovanni Martinelli, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, and Michele Baccarani

Disclosures: This study has been supported by: GIMEMA Onlus, BolognAIL, European LeukemiaNet. Novartis Oncology Italy provided the drug free-of-charge and a limited, fully unrestricted, support. Conflicts of interests: F.C. has acted as a consultant for and received honoraria from Novartis, Bristol-Myers Squibb, Pfizer and ARIAD; M. Breccia has acted as a consultant for Bristol-Myers Squibb and Novartis, Pfizer, Ariad; G.G. has acted as a consultant and received honoraria from Novartis and Bristol-Myers Squibb; M.T. has acted as a consultant for Novartis, Bristol-Myers Squibb, and ARIAD Pharmaceuticals and served on the speakers' bureaus of Novartis, Bristol-Myers Squibb, and ARIAD Pharmaceuticals; F.P. received research support from Novartis, served as advisor for Novartis, Bristol-Myers Squibb, and ARIAD Pharmaceuticals, and received lecture fees from Novartis and Bristol-Myers Squibb; G.S. has acted as a consultant for and received honoraria from Bristol-Myers Squibb, Novartis, ARIAD Pharmaceuticals, and Celgene; G.R. has acted as a consultant for Novartis, Bristol-Myers Squibb, ARIAD Pharmaceuticals and Pfizer and served on the speakers' bureaus of Novartis, Bristol-Myers Squibb, and Roche; M. Baccarani received honoraria from Novartis, Bristol-Myers Squibb, Pfizer, and ARIAD Pharmaceuticals and served on the speakers' bureaus of Novartis and Bristol Myers-Squibb; the remaining Authors had not relevant conflicts of interest to disclose.

Contributions: F.C., F.P., G.S., G.R. and M. Baccarani designed the study; F.C. M. Breccia and G.G. collected and analyzed the data; F.C., M. Breccia, G.R. and M. Baccarani wrote the first draft of the manuscript. B.M., M.D., F.S., AM.C., P.A., M.T., E.T., G.V., M.G., M.S., L.L., G.B., SF.C., MT.B., S.S., M.C., G.M. contributed to the collection of the data and reviewed the manuscript to the final report.